Trials / Completed
CompletedNCT06906809
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
A Phase 1, Open-label, Fixed-sequence, Crossover Study to Investigate the Effect of Coadministration of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-16673 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the effect of coadministration of phenytoin or itraconazole on the pharmacokinetics of BGB-16673 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-16673 | Administered orally |
| DRUG | Itraconazole | Administered orally |
| DRUG | Phenytoin | Administered orally |
Timeline
- Start date
- 2025-04-03
- Primary completion
- 2025-10-13
- Completion
- 2025-10-13
- First posted
- 2025-04-02
- Last updated
- 2025-11-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06906809. Inclusion in this directory is not an endorsement.